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Cytomegalovirus (CMV) infection can cause significant complications after transplantation, 
but recent emerging data suggest that CMV may paradoxically also exert beneficial 
effects in two specific allogeneic transplant settings. These potential benefits have 
been underappreciated and are therefore highlighted in this review. First, after alloge-
neic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) 
using T-cell and natural killer (NK) cell-replete grafts, CMV reactivation is associated 
with protection from leukemic relapse. This association was not observed for other 
hematologic malignancies. This anti-leukemic effect might be mediated by CMV-
driven expansion of donor-derived memory-like NKG2C+ NK and Vδ2negγδ T-cells. 
Donor-derived NK cells probably recognize recipient leukemic blasts by engagement 
of NKG2C with HLA-E and/or by the lack of donor (self) HLA molecules. Vδ2negγδ 
T  cells probably recognize as yet unidentified antigens on leukemic blasts via their 
TCR. Second, immunological imprints of CMV infection, such as expanded numbers 
of Vδ2negγδ T cells and terminally differentiated TCRαβ+ T cells, as well as enhanced 
NKG2C gene expression in peripheral blood of operationally tolerant liver transplant 
patients, suggest that CMV infection or reactivation may be associated with liver 
graft acceptance. Mechanistically, poor alloreactivity of CMV-induced terminally dif-
ferentiated TCRαβ+ T cells and CMV-induced IFN-driven adaptive immune resistance 
mechanisms in liver grafts may be involved. In conclusion, direct associations indicate 
that CMV reactivation may protect against AML relapse after allogeneic HSCT, and 
indirect associations suggest that CMV infection may promote allograft acceptance 
after liver transplantation. The causative mechanisms need further investigations, but 
are probably related to the profound and sustained imprint of CMV infection on the 
immune system.
Keywords: cytomegalovirus infections, hematopoietic stem cell transplantation, solid organ transplantation, 
leukemia, tolerance
Abbreviations: CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; SOT, 
solid organ transplantation; LT patient, liver transplant patient; LTx, liver transplantation; ALL, acute lymphoblastic leukemia 
(ALL); CML, chronic myeloid leukemia; MDS, myelo-dysplastic syndrome (MDS); a/cGVHD, acute/chronic graft versus host 
disease; KIR, killer cell immunoglobulin-like receptors.
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inTRODUCTiOn
While the positive impact of host–microbiota interaction on 
human health is being extensively studied in recent years, pos-
sible beneficial effects of life-long persistent viruses on human 
health remain a whole new world to explore. One of the most 
prevalent viruses among humans is cytomegalovirus (CMV). 
The sero-prevalence of CMV ranges from 30 to 100% depend-
ing on socioeconomic and ethnic background. CMV generally 
remains quiescent in healthy individuals, but can cause severe 
disorders in immunocompromised individuals, such as patients 
after hematopoietic stem cell transplantation (HSCT) or solid 
organ transplantation (SOT). Paradoxically, accumulating 
recent evidence suggests that CMV infection after transplanta-
tion may also have beneficial effects, particularly in protection 
against leukemic relapse following HSCT for acute myeloid 
leukemia (AML) and in promoting graft acceptance after liver 
transplantation (LTx). Recent research has shed first light on 
potential immunological mechanisms behind these surprising 
beneficial effects. Here, we discuss recent evidence for these two 
potential benefits of CMV infection after transplantation and 
emerging insights into the immunological mechanisms that may 
be involved.
AnTi-LeUKeMiC eFFeCT OF CMv 
ReACTivATiOn AFTeR ALLOGeneiC 
HSTC FOR AML
Cytomegalovirus reactivation is a frequent and major complica-
tion after HSCT, causing a variety of organ-specific diseases, 
including pneumonia, encephalitis, and gastrointestinal disease. 
Prior to the age of prophylactic and pre-emptive treatment of 
CMV reactivation, CMV pneumonia was the most common 
infectious cause of death after HSCT. Despite, advances in diag-
nostic techniques and treatment strategies, CMV seropositivity 
remains to be associated with inferior outcome, especially after 
myeloablative HSCT (1–3). However, paradoxical observations 
show that CMV reactivation may protect against leukemic relapse 
after allogeneic HSCT for AML go back to the mid-1980s (4), 
and have been confirmed in a series of recent studies which we 
summarize in Table 1.
In a homogeneous cohort of adult AML patients monitored 
by the pp65 antigenemia assay and treated with preemptive 
anti-CMV therapy, patients with early CMV replication after allo-
HSCT had a significantly reduced risk to develop relapse within 
10 years after transplantation (5). In a large cohort of allo-HSCT 
patients treated for different hematologic malignancies, Green 
et al. confirmed the anti-leukemia effect of early CMV replication 
detected by pp65 in AML patients, but did not observe such effect 
in acute lymphoblastic leukemia (ALL), chronic myeloid leuke-
mia (CML), lymphoma, and myelodysplastic syndrome (MDS) 
patients (6). Interestingly, pre-transplant CMV seropositivity 
was associated with an increased risk of relapse, which was con-
firmed in another study (1). Therefore, not pre-transplant CMV 
serostatus, but actual CMV reactivation seems to contribute to 
the observed beneficial effect.
The association between early CMV replication after allo-
HSCT and reduction of AML relapse risk was further confirmed 
by four independent recent studies from different countries 
(7–10). However, this association was not observed in patients 
who did not receive a myeloablative conditioning regimen (7) 
or were treated with an in vivo T-cell depleting therapy, such as 
ATG or alemtuzumab (10, 11). In three of these studies, CMV 
reactivation was determined by PCR. In contrast, one recent 
registry study, included 5,310 AML patients, showed no benefit 
of CMV reactivation for AML relapse risk after allo-HSCT (12). 
However, in this study 28% of AML patients did not receive 
myeloablative therapy and 27% of AML patients were treated by 
in vivo T/NK-cell depleting therapy. In addition, the methods for 
evaluation of CMV reactivation were unknown, which may have 
resulted in different definitions of CMV reactivation. A recent 
meta-analysis of 6 studies, including the recent registry study 
(12), with 8,511 AML patients who received mainly T-cell 
replete grafts and were not treated with T-cell depleting therapy, 
confirmed that CMV reactivation after allo-HSCT results in 
a substantial reduction of the risk of relapse (HR =  0.6, 95% 
CI = 0.43–0.84, P = 0.003) (13).
Thus, the evidence of a protective association between CMV 
replication and leukemic relapse in AML patients appears compel-
ling, but only under specific transplantation conditions (7, 10, 11). 
However, it should be emphasized that only three studies repor-
ted an improved overall survival in AML patients with CMV 
replication after HSCT (5, 8, 10), while the majority of studies 
found that the anti-leukemic effect did not translate into improved 
survival. Indeed, other studies found either no difference in sur-
vival between patients with and without CMV replication (6, 7) 
or reported that CMV replication was associated with worse 
survival due to increased non-relapse mortality (9, 12).
The only evidence available in the cord blood transplanta- 
tion setting is a recent registry study (14), which showed a trend 
to reduced AML relapse in patients with CMV reactivation. 
However, like in the registry study of Teira et al. (12), the methods 
used to detect CMV reactivation are unknown, and part of the 
patients received T-cell depleting therapy.
Whether CMV reactivation can protect against relapse after 
allo-HSCT for other hematological malignancies is controver-
sial. While Ito et al. found a decreased risk of relapse in CML 
patients after CMV reactivation within 100 days after allo-HSCT 
(15), two other studies did not confirm this finding (6, 9). Most 
studies did not observe any beneficial effect of CMV reactiva-
tion after allo-HSCT for acute lymphoblastic leukemia (ALL), 
myelodysplastic syndrome (MDS), or lymphomas (6, 9, 14, 16), 
but a recent study by Koldehoff et al. reports a reduced relapse 
incidence in non-Hodgkin lymphoma (NHL) patients (17). 
Because of contradictory results reported for other hematological 
malignancies, results on associations between CMV reactivation 
and relapse after allo-HSCT derived from mixed populations of 
patients with different hematological malignancies are difficult 
to interpret (3, 18).
In addition, apart from one study where more severe (grade 
II–IV) acute GVHD was observed in patients with CMV reac-
tivation (10), it was not associated with acute or chronic GVHD 
and remained an independent risk factor for AML relapse in 
(Continued)
TABLe 1 | Summary of recent studies on the association of post-transplant Cytomegalovirus (CMV) replication and relapse of hematological malignancies after HSCT.
Study  
(Ref.)
effect Patients Adults/ 
pediatric  
patients
Myeloablative 
pre-
conditioning
T/nK- 
depleted  
graft
Antibody-
based  
in vivo  
T-cell 
depletion
Donors Stem cell 
source
CMv dete- 
ction
endpoint Relapse rate effect of  
CMv 
reactivation  
on AML 
relapse
Comments
with  
CMv 
reactivation
without  
CMv 
reactivation
P-value
Elmaagacli 
et al. (5)
Positive  
in AML
AML n = 266 Adults All No No Sibs 118 
(44%); 
MUD 148 
(56%)
BM 45  
(17%);  
PBSC 221 
(83%)
pp65 anti- 
genemia
Cumulative 
incidence of 
AML relapse at 
10 years after 
HSCT = 33% 
(95% CI, 
27–40%)
10-year CIR 
AML 9%
10-year CIR 
AML 42%
<0.0001 aCMV infection: 
HR = 0.2, 95% 
CI = 0.1–0.4, 
P < 0.0001
Manjappa 
et al. (7)
Positive  
in AML
AML n = 264 Adults 206 (78%) no 46 (17%)  
ATG
MRD 108 
(41%); 
MUD 156 
(59%)
BM 23  
(9%);  
PBSC 240 
(91%)
PCR Cumulative 
incidence of 
AML relapse 
at 6 years after 
HSCT = 43%
6-year CIR 
AML 38.9%
6-year CIR 
AML 59%
0.03 aCMV infection: 
HR = 0.53,
95% CI =  
0.33–0.83,
P = 0.015
Effect  
restricted 
to patients 
receiving 
myelo-ablative 
conditioning
Jang  
et al. (8)
Positive  
in AML
AML n = 74 Median  
age 35;  
range  
15–59 years
68 (92%) Not men- 
tioned
11 (15%)  
A TG or 
alemtu- 
zumab
MRD 31 
(42%); 
MUD 43 
(58%)
BM 5 (7%); 
PBSC 69 
(93%)
PCR Cumulative 
incidence of 
AML relapse 
at 5 years after 
HSCT = 31%
Patient numbers not mentioned aCMV infection: 
HR = 0.21,
95% CI = 
0.08–0.54,
P = 0.001
Green  
et al. (6)
Positive  
in AML
AML n = 761
ALL n = 322
CML n = 646
Lymphoma 
n = 254
MDS n = 371
2,306 adults/ 
260 children
659 (87%)  
of AML  
patients
39 (5%) of  
AML 
patients
Not  
mentioned
Sibs 397 
(52%); 
MUD 351 
(46%); 
haplo 12 
(2%)
BM 301 
(40%);  
PBSC 460 
(60%)
pp65 anti- 
genemia
Cumulative 
incidence of 
AML relapse 
at 1 year after 
HSCT = 25.2%
1-year CIR 
AML 26.5%
1 year CIR 
AML 32.7%
0.19 aCMV  
infection: 
HR = 0.56, 
95% CI = 0.3–
0.9, P = 0.02c
Effect  
restricted to 
AML patients 
and no effect  
on overall 
mortality
Takenaka 
et al. (9)
Positive  
in AML
AML n  
= 1836
ALL n = 911
CML n = 223
MDS n = 569
Median age 
46; range: 
16–74 years
1381 (75%)  
of AML  
patients
No No MRD 989 
(54%); 
MUD 847 
(46%)
BM 1267 
(69%);  
PBSC 569 
(31%)
pp65 anti- 
genemia
Cumulative 
incidence of 
AML relapse 
at 5 years after 
HSCT = 26.5%
5-year CIR 
AML 22.4%
5-year CIR 
AML 29.6%
<0.01 aCMV  
infection: 
HR = 0.77, 
95%C = 
0.59–0.99, 
P = 0.04
Effect  
restricted to 
AML patients
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Study  
(Ref.)
effect Patients Adults/ 
pediatric  
patients
Myeloablative 
pre-
conditioning
T/nK- 
depleted  
graft
Antibody-
based  
in vivo  
T-cell 
depletion
Donors Stem cell 
source
CMv dete- 
ction
endpoint Relapse rate effect of  
CMv 
reactivation  
on AML 
relapse
Comments
with  
CMv 
reactivation
without  
CMv 
reactivation
P-value
Bao  
et al. (10)
Positive  
in AML  
sub- 
group
AML 
n = 227
Adults  
+ children,  
median age 
35; range 
2–63 years
All No 117 (52%)  
ATG
Sibs 110 
(49%), 
MUD 57 
(25%), 
haplo 60 
(26%)
BM 50  
(22%),  
PBSC  
125 (55%), 
BM +  
PBSC  
52 (23%)
PCR Cumulative 
incidence of 
AML relapse 
at 3 years after 
HSCT = 26%
3-year CIR 
AML 22%
Subgroup: 
non ATG
patients 
3-year CIR
AML 8.9%
3-year CIR 
AML 29.7%
Subgroup: 
non ATG
patients 
3-year CIR 
AML
26.7%
0.237 
0.016
aCMV  
infection: H  
R = 0, 28,  
95%  
CI = 0.1–0.79, 
P = 0.016
Effect  
restricted to 
subgroup of 
patients NOT 
receiving A TG 
in conditioning 
(n = 110)
Ramanathan  
et al. (14)
Positive  
trend in  
AML
AML  
n = 925
ALL  
n = 759
Adults  
+ children,  
median age  
28; range 
1–79 years
680 (74%) of 
AML patients
Not men- 
tioned
Part of 
patients, 
number not 
mentioned
CB CB Unknown Cumulative 
incidence of 
AML relapse 
at 3 years after 
HSCT = 35%
Patient numbers not mentioned aCMV  
infection: 
HR = 0.895% 
CI = 0.62–1.04, 
P = 0.097
Trend  
restricted to 
AML patients
Teira  
et al. (12)
Nega tive  
in AML
AML  
n = 5310
ALL  
n = 1883
CML  
n = 1079
MDS  
n = 1197
Median  
age 48;  
range 
1–83 years
3,809/5310 
(72%)
149/5, 
310 (3%)
1,439/5, 
310 (27%)
Sibs  
4071 
(43%); 
MUD  
3481 
(37%)
BM 2475 
(26%); 
PBSC  
6994  
(74%)
Unknown Cumulative 
incidence of 
AML relapse 
at 3 years after 
HSCT = 38%
Patient numbers not mentioned aCMV  
infection: 
HR = 0.97 
95%CI = 0.86–
1.1, P = 0.6  
(all AML pts)
Also no  
effect in ALL, 
CML, MDS
Ito et al.  
(15)
Positive  
in CML
CML n = 110 Adults  
+ children,  
median  
age 36;  
range 
13–69 years
97 (88%) 97 (88%) No Sibs 110 
(100%)
BM 27 
(25%), 
PBSC 83 
(75%)
pp65 anti- 
genemia  
and PCR
Cumulative 
incidence 
of CML 
relapse = 49% 
relapse after 
median follow-
up of 6–2 years
Patient numbers not mentioned aCMV  
infection: 
HR = 0.533,
95% CI = 0.29 
–0.99,
P = 0.045
Koldehoff 
et al. (17)
Positive  
in NHL
B-cell 
lymphoma 
n = 94
T- and NK cell 
neoplasms 
n = 42
Adults 107 (79%) Not men- 
tioned
57 (42%)  
ATG
Sibs 36 
(26%), 
MUD 80 
(59%), 
MUD-MM 
20 (15%)
BM 11  
(8%);  
PBSC 125 
(92%)
pp65 anti-
genemia  
and PCR 
(after June 
2011)
Cumulative 
incidence of 
NHL relapse 
at 5 years after 
HSCT = 31%
5-year CIR 
NHL 22%
5-year CIR 
NHL 38%
 < 0.013 aCMV  
infection: 
HR = 0.29, 
95%CI = 0.11 
–0.76, 
P < 0.014
TABLe 1 | Continued
(Continued)
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Study  
(Ref.)
effect Patients Adults/ 
pediatric  
patients
Myeloablative 
pre-
conditioning
T/nK- 
depleted  
graft
Antibody-
based  
in vivo  
T-cell 
depletion
Donors Stem cell 
source
CMv dete- 
ction
endpoint Relapse rate effect of  
CMv 
reactivation  
on AML 
relapse
Comments
with  
CMv 
reactivation
without  
CMv 
reactivation
P-value
Mariotti  
et al. (16)
Negative 
in NHL
B-cell 
lymphoma 
n = 265
Adults 75 (26%) No 124 (45%) 
ATG or  
alemtu- 
zumab
Sibs 147 
(55%), 
MUD 50 
(19%), 
MUD- 
MM 68 
(26%)
BM 26 
(10%), 
PBSC  
239 (90%)
pp65 
antigene- 
mia
Cumulative 
incidence  
of B-cell  
lymphoma 
relapse at 
5 years after 
HSCT = 42%
5-year CIR 
NHL 34%
5-year CIR 
NHL 50%
0.42 aCMV infection: 
HR = 1.0, 95% 
CI = 0.6–1.6; 
P = 0.9
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; CIR, cumulative incidence of relapse; CML, chronic myeloid leukemia; D/R, donor/recipient; haplo, haploidentical donor; MDS, 
myelo-dysplastic syndrome; MM, mismatched; MRD, matched related donor allogeneic HSTC; MUD, matched unrelated donor allogeneic HSCT; NHL, non Hodgkin lymphoma; PBSC, peripheral blood stem cells; sib, sibling donor 
allogeneic HSCT.
aMultivariate analysis.
bCenter for International Blood and Marrow Transplant (CIBMTR) database.
cEffect calculated on cumulative.
TABLe 1 | Continued
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multivariate analyses in which GVHD was included (Table S1 
in Supplementary Material), however, this was not always repor-
ted. Available data, therefore, suggest that protection of AML 
relapse cannot be merely explained by an increased CMV-induced 
allogeneic immune response.
POSSiBLe MeCHAniSMS OF  
AnTi-LeUKeMiC eFFeCTS OF  
CMv AFTeR ALLO-HSCT FOR AML
Cytomegalovirus reactivation does not protect against AML 
relapse when T- and/or NK cells are depleted in vivo or in vitro, 
suggesting that CMV reactivation requires a reconstitution of 
donor-derived T cells and/or NK cells to reduce leukemic relapse 
(7, 10, 11). Although recently a direct pro-apoptotic effect of 
CMV on acute leukemia cell lines has been shown (19), CMV 
is generally thought to be non-cytolytic, but instead to protect 
infected cells from apoptosis in order to delay cell death and 
maintain viral replication. Therefore, the anti-leukemic effects of 
CMV infection after allo-HSCT for AML are probably mainly 
caused by cross-reactivity of CMV-stimulated innate and adap-
tive immune responses with cancer cells. CMV infection leaves 
a deep and life-long imprint on the human immune system. Two 
types of immune cells that are expanded during CMV infection 
have been postulated to be involved in CMV-induced protection 
against AML. These are natural killer (NK) cell and Vδ2negγδ 
T cells (Figure 1).
A CMV reactivation after allogeneic HSCT induces a long- 
lasting expansion of, mainly donor-derived, memory-like NK cells, 
or CMV-adapted NK cells, with enhanced functional properties 
compared to conventional NK  cells. This CMV-induced memory- 
like NK-cell population is characterized by low expression 
of CD56, expression of CD57, lack of the inhibitory NKG2a 
receptor, and expression of the activating heterodimeric rece-
ptor CD94-NKG2C (20, 21). The memory-associated features 
of these CMV-induced NK include secondary expansion and 
enhanced capacity to produce IFN-γ upon CMV reactivation 
(20, 22, 23). Once induced, their expansion is not limited to 
CMV reactivation, as stimulation via the low affinity Fc receptor 
IIIa (CD16) by IgG, as well as pro-inflammatory cytokines, can 
contribute to the expansion, persistence, and functional proper-
ties of CMV-induced memory-like NK  cells (21, 24, 25). The 
enhanced functional properties of CMV-induced donor-derived 
NKG2C+ memory NK cells compared to conventional NK cells 
are caused by epigenetic remodeling resulting in increased pro-
liferative responses as well as cytokine production (21, 24, 26). 
Interestingly, expansion of these cells after HSCT is not only 
associated with protection from CMV reactivation (27), but also 
trended to be associated with a reduced rate of AML relapse (28).
The mechanism by which this NK-cell subset recognizes 
leukemic blasts may be related to the switch in expression from 
the inhibitory NKG2A to the activating NKG2C, both receptors 
for HLA-E, which is expressed on leukemic blasts. Alternatively, 
in partially HLA-mismatched HSCT, the anti-leukemic effect 
may be related to the general mechanism of NK-cell self-tolerance, 
which is mediated by inhibitory receptors, such as killer cell 
immunoglobulin-like receptors (KIR), that recognize self-MHC 
class I molecules. According to the “missing-self hypothesis,” 
recipient AML cells can be the target for cytotoxicity of donor-
derived NKG2C+ NK cells, induced upon CMV infection, as they 
lack donor HLA molecules (23).
γδ T cells are involved in the first line of host immune defense 
to microbial pathogens and expanded in the circulation during 
CMV infection. They also show some adaptive features, such 
as accelerated expansion upon CMV reactivation (29, 30). The 
main γδ T-cell subset in peripheral blood expresses T-cell recep-
tors encoded by the Vδ2 and Vδ9 gene segments and is referred 
to as Vδ2posγδ T-cells. γδ T cells that express Vδ1, Vδ3, or Vδ5, 
but not Vδ2, TCR are collectively designated as Vδ2negγδ T-cells. 
The latter reside mainly in intestinal and skin epithelia, spleen, 
and liver (30). Interestingly, a strong and durable expansion of 
circulating Vδ2negγδ T cells occurs upon CMV reactivation after 
allo-HSCT (31, 32). This phenomenon is unique for CMV infec-
tion and does not occur after infections with other viruses after 
HSCT (31). Involvement of CMV-induced Vδ2negγδ T  cells in 
protection from leukemic relapse has been suggested by studies 
showing that expansion of circulating Vδ2negγδ T cells after HSCT 
is associated with improved leukemia-free survival (33) and that 
CMV-reactive Vδ2negγδ T  cells isolated from CMV-infected 
HSCT recipients cross-react to primary AML cells (32).
Vδ2negγδ T cells recognize leukemic blasts via their TCR, while 
CD8αα probably serves as a co-receptor in antigen recognition 
(29). They probably recognize novel antigens in similar manner 
as Vδ2posγδ T-cells. Quite different from αβ-TCR, Vδ2posγδ TCR 
recognizes conformational changes in proteins in an antibody-
like way (34–36). In addition, natural cytotoxicity receptors, es- 
pecially NKp30, may play a role in tumor cell recognition by 
Vδ2negγδ T cells (37).
ASSOCiATiOn BeTween CMv inFeCTiOn 
AnD GRAFT ACCePTAnCe in SOT
In experimental animal SOT models, both acute CMV infection 
and CMV reactivation have been shown to prevent or disrupt 
graft acceptance, which is thought to result from cross-reactivity 
of virus-specific T cells to allo-antigens (38). In addition, in the 
clinical setting, CMV infection after SOT is generally associated 
with an increased risk of acute and chronic allograft rejection 
and like for HSCT, CMV infection is a major cause of morbidity 
and mortality. These data have been summarized in excellent 
reviews (39–41). Therefore, sophisticated strategies have been 
implemented to detect CMV early and treat pre-emptively.
However, a main issue in the interpretation of the observed 
associations between CMV infection and graft rejection is that 
rejections often occur before CMV infection, and, therefore, it 
is difficult to prove cause and effect (39, 42). Two recent studies 
suggest that the link between CMV infection and acute as well as 
chronic rejection after kidney transplantation are far less signifi-
cant than previously thought (42, 43). A CMV infection signifi-
cantly impacts the immune system leaving a clear fingerprint of 
memory inflation in the T-cell compartment, resembling features 
of immune aging or senescence (44, 45). This memory inflation is 
FiGURe 1 | Schematic overview of (potential) beneficial effects of cytomegalovirus (CMV) infection after transplantation. This schematic overview illustrates the 
(potential) beneficial effects exhibited by different CMV-induced immune cell subsets and intra-graft IFN-signaling pathways after transplantation. Compelling 
evidence exists for anti-leukemic effects of CMV-induced donor-derived memory-like natural killer (NK) cells after hematopoietic stem cell transplantation (HSCT)  
in acute myeloid leukemia (AML) patients, and two mechanisms have been described. One involves enhanced expression of the activating NK-receptor NKG2C,  
at the expense of the inhibitory NKG2A, interacting with HLA-E expressed by AML blasts. The other mechanism involves the “missing self” principle, as recipient 
tumor cells do not express donor HLA class I and are, therefore, a target for killing by donor-derived NK cells as a result of lack of inhibition via donor HLA class 
I-recognizing inhibitory killer cell immunoglobulin-like receptors. CMV-induced TCRδ2− γδ T cells have also been associated with anti-leukemic effects after HSCT, 
probably via recognition of an as yet unknown ligand by their TCR. Evidence implicating CMV-specific TCR αβ T cells in preventing AML relapse after HSCT is 
lacking. In addition, CMV-induced immune cell subsets have been associated with graft acceptance and liver-transplant tolerance. Evidence merely consists of 
associations and no detailed mechanistic insights are available yet. Induction of terminally differentiated TCRαβ T cells with low alloreactivity by CMV infection in 
various types of solid organ transplantations may be involved in development of graft acceptance. CMV-induced circulating TCRδ2− γδ T cells are associated  
with liver transplant tolerance, but probably not functionally involved. Overexpression of NKG2C in peripheral blood is associated with both CMV infection and  
graft acceptance after liver transplantation, but whether a causal exists between NKG2C+ NK cells and graft acceptance is unknown. Apart from CMV-induced 
immune cell subsets, intra-graft IFN-α, β, and γ production, which can be induced by CMV, has been associated with liver transplant tolerance by induction of 
PD-L1 expression in the graft, thereby counteracting the host immune response.
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accelerated during CMV reactivation under immunosuppressive 
medication after SOT (46). Nevertheless, CMV-specific T  cells 
that cross-react to donor cells are only transiently present in 
the circulation of CMV-infected kidney transplant recipients, 
and their presence is not associated with inferior graft function 
(47). Several recent studies even suggest that under certain 
conditions there may even be an opposite association between 
CMV infection and graft rejection. First, in elderly kidney trans-
plant recipients, CMV seropositivity was associated with CD4+ 
T-cell immune senescence and freedom of acute rejection (48). 
Second, donor-specific T-cell hypo-responsiveness, i.e., reduced 
frequencies of donor-specific, but not of third party-specific 
T-cells, and reduced immunological graft damage were observed 
in patients with strong CMV-specific T-cell responses after kid-
ney and heart transplantation (49, 50). Third, increased numbers 
of terminally differentiated CD8+ T-cells, as well as CD4+ T cells 
lacking CD28, both T-cell subsets associated with CMV latency, in 
the circulation prior to kidney transplantation have been associ-
ated with a lower risk for acute rejection (51, 52). Finally, primary 
CMV infection following LTx is associated with accumulation of 
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terminally differentiated CD8+ T cells in the circulation as well 
as with donor-specific CD8+ T-cell hypo-responsiveness and a 
reduced incidence of acute rejection episodes late after trans-
plantation (53).
As compared with other solid organ grafts, liver grafts display 
unique immunological features, and LTx is the only setting in 
which a significant proportion of patients can eventually discon-
tinue immunosuppressive medication without undergoing rejec-
tion, a phenomenon known as spontaneous operational tolerance 
(54). Recent prospective immunosuppression withdrawal studies 
have shown that operational tolerance can be achieved in about 
40% of stable adult LTx patients and 60% of stable pediatric LTX 
patients (55–57). Interestingly, studies from two different centers 
found expanded numbers of peripheral Vδ1+γδ T cells and an 
increased peripheral Vδ1/Vδ2 γδ T-cell ratio in tolerant com-
pared to non-tolerant LTx patients (58–60). In addition, tolerant 
pediatric LTx recipients exhibit an increased intra-graft Vδ1/Vδ2 
ratio (61). A high peripheral Vδ1/Vδ2 γδ T-cell ratio has even 
successfully been used as a biomarker to select liver transplant 
(LT) patients for immunosuppression withdrawal (56). Since, 
durable expansion of circulating Vδ1+γδ T cells and an increased 
peripheral Vδ1/Vδ2 ratio after CMV infection has been observed 
in all types of SOT, including LTx (53, 62–65), these observations 
suggest an association between CMV infection and tolerance 
after LTx. Such relationship is further supported by a recent study 
which showed that primary CMV infection after LTx is associated 
with both expansion of circulating Vδ1+γδ T  cells and donor-
specific CD8+ T cell hypo-responsiveness (53). CMV-responsive 
Vδ2− γδ T  cells have been implicated in antibody mediated 
rejection after kidney transplant recipients (66), suggesting a 
different role for these cells after liver transplantation, which may 
be related to the lower impact of antibodies in liver graft rejec- 
tion compared to kidney graft rejection.
Increased numbers of circulating terminally differentiated CD8+  
T cells expressing co-inhibitory receptors is another feature sha-
red by CMV infection (53, 67) and operational tolerance (56) 
after LTx, again suggesting a possible association. Finally, com-
parison of gene expression patterns in circulating leukocytes 
between tolerant and non-tolerant LTx recipients revealed over- 
expression of NK-cell-related genes in tolerant patients. Interes-
tingly, KLRC4, one of genes encoding NKG2C, which is induced 
on circulating NK cells by CMV infection and reactivation both 
after HSCT (20–22, 27) and SOT, including LTx (68–70), was 
found to be over-expressed in tolerant LTx patients in two dif-
ferent cohorts (59, 71).
Thus, although a direct association between CMV infection 
and graft acceptance after LTx has not been demonstrated, the 
presence of sustained immunological imprints of CMV infection 
in operationally tolerant, but not in non-tolerant, LT patients is 
strongly suggestive for such association.
POSSiBLe MeCHAniSMS OF  
GRAFT ACCePTAnCe in SOT  
AFTeR CMv inFeCTiOn
How CMV restrains alloreactivity after LTx remains elusive, and 
whether CMV-induced peripheral immune cell signatures play 
a causative role in promoting LT tolerance is as yet unknown. 
Although Vδ1+γδ T  cells under certain conditions may have 
immune-regulatory properties (72, 73), it is as yet unknown 
whether they can contribute to liver graft acceptance. However, 
the massive peripheral expansion of terminally differentiated 
CD8+ T cells expressing co-inhibitory receptors upon CMV infec-
tion after LTx may contribute to reduced T-cell alloreactivity to 
organ grafts, since these cells show impaired functional responses 
to allo-antigens (53, 67) (Figure  1). In addition, as terminally 
differentiated CD8+ T cells poorly infiltrate in organ grafts, they 
might not contribute to graft rejection even when functionally 
competent to respond to allo-antigens (53, 74).
Cytomegalovirus infection of the liver graft may also promote 
resistance of liver grafts to allogeneic attack by triggering type I 
interferon production (75) and recruitment of T-helper 1 cells 
that produce IFN-γ (76), which is strikingly absolutely needed 
for LT tolerance in animal models (77). IFN-γ produced by 
graft-infiltrating T cells critically contributes to immunological 
tolerance of liver grafts in experimental animals by induction 
of intra-graft PD-L1 expression that leads to T-cell apoptosis 
(78). Indeed, interaction of PD-L1 expressed in the liver graft 
with the co-inhibitory receptor PD-1 on graft-infiltrating 
T  cells also counter-regulates rejection activity against liver 
grafts in humans (79) (Figure  1). Although this mechanism 
of CMV-driven graft anti-host resistance is speculative, a 
role for intra-graft interferon signaling, in the development 
of operational tolerance after LTX has been suggested by an 
immunosuppression withdrawal trial in HCV-infected LT 
patients in which operationally tolerant patients were observed 
to overexpress interferon-stimulated genes as well as PD-L1 and 
PD-1 in their liver graft (56). Such so-called “adaptive immune 
resistance” mechanisms, in which expression of immunosup-
pressive molecules, such as PD-L1, is induced in response to 
IFN type I and/or IFN-γ produced by infiltrating immune 
cells, are also utilized by tumors to escape immune attack (80). 
In addition, recent data show that IFN-type I signaling during 
chronic viral infections may promote CD8+ T cell exhaustion 
and impair memory T-cell responses against unrelated antigens 
(81, 82), connecting IFN-signaling to terminal differentiation 
and exhaustion of CD8+ T cells.
Finally, one or more of the well-established immune evasion 
strategies of CMV to establish latency may be involved, such as 
production of viral IL-10, which may exert systemic immunosup-
pressive effects (83).
COnCLUDinG ReMARKS
Cytomegalovirus infection, although generally disadvantageous 
in immunosuppressed subjects, paradoxically has beneficial 
effects in HSCT and probably also in LTx recipients. More research 
is definitely needed to substantiate and better understand these 
enigmatic observations. Whereas, the anti-leukemic effect of 
CMV infection after HSCT in AML patients is firmly established, 
prospective studies are required to investigate whether there is a 
direct association between CMV infection after LTx and deve-
lopment of allogeneic liver graft acceptance. Such studies should 
be accompanied by extensive peripheral and intra-graft immune 
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profiling to begin to understand the putative immunological 
mechanisms linking CMV infection with tolerance after LTX. 
Similarly, studies aiming to further unravel the immunological 
mechanisms linking CMV infection and prevention of AML 
recurrence after HSCT are required. Once those benefits and the 
underlying mechanisms have been firmly established, develop-
ment of therapeutic approaches to mimic the beneficial effects of 
CMV infection after HSCT for AML and after LTx becomes an 
interesting, although challenging aim. Development of a CMV 
vaccine that induces similar immunological imprints as CMV 
infections might be a way to achieve this goal.
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